AG-2/AGR2 Antibody - BSA Free

Western Blot: AG-2/AGR2 Antibody [NBP2-27393]

AG-2-AGR2-Antibody-Western-Blot-NBP2-27393-img0014.jpg

Western Blot: AG-2/AGR2 Antibody [NBP2-27393]

Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Detection of AGR2 using AGR2 antibody. MCF7 (A), Caco-2 (B) and human stomach lysate (C) probed with AGR2 antibody at 1:100. were used for this test. The higher molecular weight band of variable intensity at ~30 kDa is uncharacterized and may represent a form of AGR2.

Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393]

Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Staining of human adenocarcinoma of the breast stained with AGR2 antibody (2 ug/ml), peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.

Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] -

Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] - Staining of AGR2 using AGR2 antibody. Formalin-fixed, paraffin-embedded normal colon tissue probed with AGR2 antibody at 1:100 dilution.

Western Blot: AG-2/AGR2 Antibody [NBP2-27393] -

Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - AGR2 expression in cancer cell lines of the biliary tract. A. AGR2 mRNA levels in six biliary tract cancer cell lines were measured by real-time RT-PCR. The AGR2 transcript levels were normalized against those of the GAPDH. Results shown are means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression was detected by western blot analysis with beta -actin as a loading control. The result shown is a representative of three experiments. Abbreviations: CBD, common bile duct; GB, gall bladder; AoV, ampulla of Vater; IHD, intrahepatic duct; HDB, hepatic duct bifurcation; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated [24]. Image collected & cropped by CiteAb from the following publication (http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: AG-2/AGR2 Antibody [NBP2-27393] -

Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - Alterations of tumor-associated phenotypes by overexpression of AGR2 in SNU-869 cells. A. AGR2 expression in the SNU-869 stable transfectants was verified by real-time RT-PCR. The AGR2 transcript level was normalized against that of GAPDH. Results shown are means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression in the SNU-869 stable transfectants was detected by western blot analysis with beta -actin as a loading control. The result shown is a representative of three experiments. C. Viability of the SNU-869 stable transfectants was measured by the MTT assay. Results shown are means ± standard deviations of three experiments (ANOVA P = 0.008; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.013). D. The effect of AGR2 overexpression on cell proliferation. Pulsed BrdU incorporation into the SNU-869 stable transfectants was measured by flow cytometry. Percentage of BrdU-positive cells was shown in mean ± standard deviation of four experiments (ANOVA P = 0.053; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.027). Results shown are representatives of four experiments. E. The effect of AGR2 overexpression on tumor cell invasion of SNU-869 cells. The numbers of invading cells in the transwell invasion assay were determined for SNU-869 stable transfectants. Results shown are means ± standard deviations of three experiments (ANOVA P = 0.003; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.026). Image collected & cropped by CiteAb from the following publication (http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Knockdown Validated: AG-2/AGR2 Antibody - BSA Free [NBP2-27393] -

Alterations of tumor-associated phenotypes in AGR2-silenced SNU-478 cells. A. Expression of AGR2 mRNA in SNU-478:KD (AGR2 knockdown) clones was compared with that in SNU-478:VEC (vector control) by real-time RT-PCR. The AGR2 transcript level was normalized against that of GAPDH. Results shown are means +/- standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression in SNU-478:VEC and SNU-478:KDs was detected by western blot analysis with beta -actin as a loading control. The result shown is a representative of three experiments. C. Viability of SNU-478:VEC and SNU-478:KDs was measured by the MTT assay. Results shown are means +/- standard deviations of three experiments (ANOVA P = 0.010; post hoc analysis by Bonferroni testing: KD2 vs. VEC, P = 0.016). D. Anchorage-independent growth was examined by colony formation assay in soft agar. The number of colonies formed in the soft agar assay with SNU-478:VEC and SNU-478:KDs. Results shown are means +/- standard deviations of three experiments (ANOVA P = 0.000; post hoc analysis by Bonferroni testing: KD1-3 vs. VEC, P = 0.000). E. The number of invading cells in the transwell invasion assay with SNU-478:VEC and SNU-478:KDs. Results shown are means +/- standard deviations of three experiments (ANOVA P = 0.042). F. Drug sensitivity of SNU-478:VEC and SNU-478:KDs was measured by the MTT assay. Cells plated in a 96-well plate were treated with gemcitabine (20 μg/mL), cisplatin (0.5 μg/mL), or 5-FU (50 μg/mL), and the MTT assay was carried out on day three of the treatments. (ANOVA P = 0.000 for gemcitabine; ANOVA P = 0.048 for cisplatin; ANOVA P = 0.001 for 5-FU). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/25367337), licensed under a CC-BY license. Not internally tested by Novus Biologicals.